论文部分内容阅读
研究系统性硬化(systemic sclerosis,SSc)患者体内高迁移率族蛋白B1(HMGB1)和可溶性晚期糖基化终产物受体(sRAGE)蛋白和基因表达水平,探讨这两种炎症性蛋白在SSc发病过程中的作用。收集肢端型硬皮病(lSSc)30例、弥漫型硬皮病(dSSc)30例和正常人40例。运用ELISA方法检测血浆中HMGB1、sRAGE的含量,用real-time PCR方法检测外周血细胞中这两个因子的mRNA相对表达量,并对临床和实验室指标进行相关分析。与正常对照组相比,lSSc和dSSc患者血浆HMGB1含量[(150.31±65.52)μg/L,(151.07±81.32)μg/L],高于正常对照组(112.89±60.57)μg/L(P均<0.05);两组患者血浆sRAGE[(395.06±158.38)ng/L,(425.57±212.35)ng/L]水平高于对照组(329.47±107.03)ng/L(P均<0.05)。两组患者血浆HMGB1和sRAGE的浓度分别两两之间存在正相关(r=0.349,P<0.05;r=0.211,P<0.05)。两种类型硬皮病患者外周血细胞HMGB1mRNA相对表达量均高于正常对照组(P均<0.05),而sRAGE mRNA相对表达量较对照组均无明显差异。伴有累及肺部或肾脏的SSc患者血浆HMGB1、sRAGE水平明显高于无累及肺部或肾脏的患者(P均<0.05);抗组蛋白抗体或抗RNA聚合酶Ⅲ抗体阳性的SSc患者血浆HMGB1、sRAGE水平明显高于抗体阴性组,而抗着丝点抗体阳性组SSc患者血浆HMGB1、sRAGE水平低于抗体阴性组患者(P<0.05)。HMGB1和sRAGE在系统性硬化患者体内表达明显升高,提示患者体内存在着明显的炎症反应,且这两个蛋白含量与某些临床实验室指标有显著相关性,表明其可能在疾病的发病机制中起着一定重要作用,可望成为评价疾病严重性的新指标。
To investigate the expression of HMGB1 and sRAGE in patients with systemic sclerosis (SSc) and to explore the relationship between the expression of HMGB1 and sRAGE in patients with SSc The role of the process. 30 cases of acral scleroderma (lSSc), 30 cases of diffuse scleroderma (dSSc) and 40 cases of normal people were collected. The contents of HMGB1 and sRAGE in plasma were detected by ELISA. Relative mRNA expression of these two factors in peripheral blood was detected by real-time PCR. The correlation between clinical and laboratory parameters was analyzed. Compared with the normal control group, the plasma levels of HMGB1 in lSSc and dSSc patients were significantly higher than those in the normal control group [(150.31 ± 65.52) μg / L, (151.07 ± 81.32) μg / L] <0.05). The plasma levels of sRAGE (395.06 ± 158.38) ng / L and (425.57 ± 212.35) ng / L] in both groups were significantly higher than those in the control group (329.47 ± 107.03 ng / L, P <0.05). Plasma concentrations of HMGB1 and sRAGE in both groups were positively correlated with each other (r = 0.349, P <0.05; r = 0.211, P <0.05). The relative expression levels of HMGB1 mRNA in peripheral blood cells in both types of scleroderma were higher than those in normal control group (all P <0.05), while the relative expression level of sRAGE mRNA in control group was not significantly different. The plasma levels of HMGB1 and sRAGE in SSc patients with pulmonary or renal involvement were significantly higher than those in patients without pulmonary or renal involvement (all P <0.05). The levels of plasma HMGB1 and anti-RNA polymerase Ⅲ antibodies in patients with SSc , SRAGE levels were significantly higher than those in antibody negative group, while plasma levels of HMGB1 and sRAGE in patients with anti-centromere antibody positive SSc were lower than those in antibody negative patients (P <0.05). The expression of HMGB1 and sRAGE in patients with systemic sclerosis significantly increased, suggesting that there is a clear inflammatory reaction in patients with these two protein content and some clinical laboratory indicators have significant correlation, indicating that it may be in the pathogenesis of the disease Plays an important role in the evaluation of the severity of the disease can be a new indicator.